These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 23584689)

  • 1. Response of retinal sensitivity to ranibizumab treatment of macular edema after acute branch retinal vein occlusion.
    Mylonas G; Sacu S; Dunavoelgyi R; Matt G; Blum R; Buehl W; Pruente C; Schmidt-Erfurth U;
    Retina; 2013 Jun; 33(6):1220-6. PubMed ID: 23584689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of retinal sensitivity and morphology during antiangiogenic treatment of retinal vein occlusion over one year.
    Kriechbaum K; Prager F; Geitzenauer W; Benesch T; Schütze C; Simader C; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2415-21. PubMed ID: 19744723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
    Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
    JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
    Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
    Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal sensitivity after intravitreal injection of bevacizumab for the treatment of macular edema secondary to retinal vein occlusion.
    Yamaike N; Tsujikawa A; Sakamoto A; Ota M; Kotera Y; Miyamoto K; Kita M; Yoshimura N
    Retina; 2009 Jun; 29(6):757-67. PubMed ID: 19289982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion.
    Ehlers JP; Decroos FC; Fekrat S
    Retina; 2011 Oct; 31(9):1856-62. PubMed ID: 21659943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
    Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
    Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
    Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
    Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bevacizumab and Ranibizumab for macular edema due to retinal vein occlusions].
    Niederhauser N; Valmaggia C
    Klin Monbl Augenheilkd; 2013 Apr; 230(4):405-8. PubMed ID: 23629792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.
    Kim M; Yu SY; Kim ES; Bae SH; Park JH; Yu HG; Kwak HW
    Ophthalmologica; 2012; 227(3):132-8. PubMed ID: 22212151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis.
    Kondo M; Kondo N; Ito Y; Kachi S; Kikuchi M; Yasuma TR; Ota I; Kensaku M; Terasaki H
    Retina; 2009 Oct; 29(9):1242-8. PubMed ID: 19672216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
    Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
    Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
    Cho HJ; Kim CG; Yoo SJ; Cho SW; Lee DW; Kim JW; Lee JH
    Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.
    Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM
    Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
    Tan MH; McAllister IL; Gillies ME; Verma N; Banerjee G; Smithies LA; Wong WL; Wong TY
    Am J Ophthalmol; 2014 Jan; 157(1):237-247.e1. PubMed ID: 24112635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microperimetric changes after intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion.
    Senturk F; Ozdemir H; Karacorlu M; Karacorlu SA; Uysal O
    Retina; 2010 Sep; 30(8):1254-61. PubMed ID: 20827142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in retinal blood flow in patients with macular edema secondary to branch retinal vein occlusion before and after intravitreal injection of bevacizumab.
    Nagaoka T; Sogawa K; Yoshida A
    Retina; 2014 Oct; 34(10):2037-43. PubMed ID: 24896136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
    Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.